LSE:RENE (ReNeuron Group)
About RENE
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
Financial Market Data copyright © 2024
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Profiles by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Financials by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2024
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Share Information by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Dividends by EDI/Mergent (USA) and TSX (CDN).
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Earnings and Analyst Ratings by Zacks.
Earnings Events by Wall Street Horizon.
Terms of Use.
ReNeuron Group (LSE: RENE) Latest News
